0HFQ.LSE AnaptysBio, Inc.

Healthcare Biotechnology London Exchange
- USD
Market cap
-
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Is 0HFQ.LSE undervalued?

Graham number

The Graham number of AnaptysBio, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

AnaptysBio, Inc. fundamental analysis

No fundamental analysis for AnaptysBio, Inc. yet.

AnaptysBio, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About AnaptysBio, Inc.

AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agr…

Full company profile